Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses, 13(14), 1163-77. presented at the 1997 Sep 20. doi:10.1089/aid.1997.13.1163. (1997).
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis, 177(5), 1230-46. presented at the 1998 May. doi:10.1086/515288. (1998).
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis, 180(2), 290-8. presented at the 1999 Aug. doi:10.1086/314895. (1999).